



The Trendlines Group’s Company Vensica Medical Advances Needle-Free Bladder Therapy to Phase 2

- *Vensica received FDA IND clearance to initiate Phase 2 study of ViXe, its needle-free Xeomin® delivery system for overactive bladder.*
- *Strategic milestone validates clinical rationale for needle-free delivery and triggers milestone payment from strategic partners.*
- *ViXe aims to transform the standard of care for 33 million Americans living with overactive bladder through a non-invasive ultrasound-based solution.*
- *The Group holds approximately 9% in Vensica, founded by Avner Geva and incubated by Trendlines.*

Misgav, Israel, 4 May 2026 — Vensica Medical (“**Vensica**”), a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (“**FDA**”) has cleared the Company’s Investigational New Drug (“**IND**”) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate Vensica’s Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® for the treatment of overactive bladder (“**OAB**”).

The Phase 2 study is expected to enroll approximately 210 patients across sites in the United States and Europe. This clinical milestone triggers a contractual development milestone payment from Vensica's strategic partners. Vensica is supported by its investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines.

Overactive bladder affects an estimated 33 million adults in the United States¹. While botulinum toxin injection is an established treatment, its invasive nature often limits patient acceptance. Vensica’s ViXe program is designed to deliver the therapy into the bladder wall without the use of needles, potentially expanding access to a much broader patient population.

Vensica’s CEO, Avner Geva, commented: “FDA clearance of this IND is an important milestone for Vensica and validates the clinical rationale behind the ViXe program. We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare.”

¹ <https://uuanj.com/men/overactive-bladder/>

Haim Brosh, CEO of Trendlines, added: “This clearance represents a key milestone in Vensica's development and follows a number of key developments recently in our portfolio, emphasizing the progress and maturity of our companies.”

About Vensica Medical Ltd.

Vensica Medical is a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases. The Company's lead program, ViXe, combines the Vibe® system with Xeomin® for the treatment of overactive bladder. For more information, please visit www.vensica.com.

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:

Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990